George W. Hebard III, M.B.A.

— Interim Principal Executive Officer and Chief Operating Officer

Mr. Hebard was appointed Interim Principal Executive Officer and Chief Operating Officer in May 2012. He joined Enzon as a director of the Company on February 27, 2012. From September 2011 to April 2012, Mr. Hebard was a Managing Director at Icahn Capital LP, the entity through which Carl C. Icahn manages investment funds. Prior to joining Mr. Icahn, from 2005 to 2011, Mr. Hebard served as a Managing Director at Blue Harbour Group, an investment firm in Greenwich, Connecticut. Prior to Blue Harbour Group, Mr. Hebard served as a Managing Director at Ranger Partners from 2002 to 2003, and prior to Ranger Partners, Mr. Hebard was an Associate at Icahn Associates Corp. from 1998 to 2002. He has an MBA from INSEAD and an A.B. in Economics from Princeton University.

Charles Conover, Ph.D., M.B.A.

— Senior Vice President, Research and Development, Program Management

Charles Conover has served as senior vice president of research & development, program management since January 2012.  Previously, Dr. Conover served in several senior roles in global project and alliance management, scientific affairs, and experimental therapeutics after first joining Enzon as a scientist in 1993.

Dr. Conover has authored more than 30 full-length articles and has received multiple awards for his contributions to research and development at Enzon.  He is a member of the Project Management Institute, the Drug Information Association, the American Association for Cancer Research, and the Controlled Release Society. He holds Ph.D. in physiology and an M.B.A. in management of innovation and technology from Rutgers University.

Andrew Rackear, J.D.

— Vice President and General Counsel

Andrew Rackear has served as Enzon’s general counsel and secretary since April 2010, and also as chief compliance officer since September 2010.  Prior to joining Enzon, Mr. Rackear served as senior vice president and general counsel for NPS Pharmaceuticals, and vice president and general counsel for Chugai Pharma USA and Amersham Biosciences Corp, where he also served as president of North American operations. 

Prior to joining the industry, Mr. Rackear engaged in litigation and commercial law practice at Marks & Murase (now Bingham McCutchen) and served as associate general counsel at Sharp Electronics Corp.  Mr. Rackear holds a J.D. from New York University School of Law.

Timothy G. Daly

— Vice President, Controller and Chief Accounting Officer

Tim Daly has served as Enzon’s vice president, controller and chief accounting officer since December 2011.  Mr. Daly has over 12 years of experience in the biotech and pharmaceutical healthcare industries.  Prior to joining Enzon, Mr. Daly served as director of finance at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company.  During his tenure with ImClone Sytems, Tim served in various operational and financial roles, including treasury and cash management, compliance and internal controls.

Mr. Daly holds a B.A.S. in accounting from Rider University